by Paul Lelieveld | Jan 20, 2021 | Meneldor News
Serial German biotech entrepreneur Dr. Ulrich Dauer appointed as new Chairman Michael Grissinger to replace Emilie Hofstetter, adding pharmaceutical deal-making and US market expertise Atriva Therapeutics is currently investigating its lead candidate ATR-002 in a...
by Paul Lelieveld | Jan 5, 2021 | Meneldor News
RESPIRE is a placebo-controlled, international, multi-center trial treating hospitalized patients with moderate to severe COVID-19 The Phase II clinical trial will evaluate efficacy, safety and pharmacokinetics of ATR-002, an orally available small molecule with a...
by Paul Lelieveld | Dec 2, 2020 | Meneldor News
Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente Sichere und hoch wirksame Medikamente sind dringend erforderlich, um COVID-19-Patienten zu versorgen und Krankenhäuser zu entlasten. Impfstoffe schützen...
by Paul Lelieveld | Oct 20, 2020 | Meneldor News
Germany, October 20, 2020 Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment European Investment Bank and Atriva Therapeutics sign financing agreement of €24 million for the research, development and clinical...
by Paul Lelieveld | Aug 11, 2020 | Meneldor News
Round led by existing investors Meneldor and High-Tech Gründerfonds Proceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development in influenza and other respiratory viral infections ATR-002 mode of action inhibits...
